Tscan Therapeutics Inc Dossier
Qualitative Analysis
Business overview
TScan Therapeutics, Inc. (Nasdaq: TCRX) is a clinical-stage biotechnology company focused on the discovery and development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The company's proprietary platform is designed to discover anti-cancer TCRs from patients with exceptional responses to immunotherapy. TScan's lead clinical program is TSC-101, which is in development for patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA Phase 1 heme trial). The company is also expanding its ImmunoBank, a repository of therapeutic TCRs recognizing diverse targets across multiple HLA types, to provide customized multiplex TCR-T therapies for solid tumors (the PLEXI-T Phase 1 trial).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A strategic pivot announced in late 2025 to focus clinical development resources on the hematologic malignancies program (specifically TSC-101 and TSC-102) while pausing active enrollment in the solid tumor clinical trials.
Expected impact: Expected to generate annual cost savings of approximately $45.0 million across 2026 and 2027, extending the company's cash runway into the second half of 2027.
Shifting the solid tumor strategy from ex vivo multiplexed TCR-T therapies to preclinical development of in vivo engineering of T cells using a lentiviral-based platform.
Expected impact: Aims to deliver a more cost-efficient, off-the-shelf, multiplexed TCR-T therapy for solid tumors without the complexities of ex vivo manufacturing.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High. Evaluates the automation of clinical manufacturing for TScan's lead candidate, TSC-101, using Cellares' Cell Shuttle and Cell Q platforms to establish a scalable and cost-efficient commercial production model.
Terms: Terms of the evaluation agreement were not publicly disclosed.
High. Utilizes TScan's TargetScan platform to identify antigens recognized by T cells in Crohn's disease patients, expanding TScan's technology into the autoimmune space.
Terms: $30 million upfront payment, with eligibility for over $500 million in success-based preclinical, clinical, regulatory, and commercial milestones, plus tiered single-digit royalties.